ASML gains after UBS calls it Europe’s top semiconductor pick By Investing.com

UBS reinstated ASML as its top European semiconductor pick and raised its price target to €1,900 from €1,600, with 2027 and 2028 EPS forecasts of €48.42 and €59.73, about 15-20% above consensus. The bank sees ASML’s underperformance, memory exposure, and High NA EUV adoption as key upside drivers, while dismissing concerns that the company will become a near-term bottleneck. ASML shares rose 3.5% in Amsterdam on the upgrade.

Analysis

ASML is the cleanest way to express a next-wave capex reacceleration without taking idiosyncratic foundry execution risk. The underappreciated second-order effect is that if lithography is not the bottleneck, spending can stay elevated deeper into the cycle because customers will be forced to keep funding adjacent steps that preserve line balance; that tends to support the whole front-end tool stack, but especially the highest-value systems where capacity scarcity preserves pricing power.

The memory angle matters more than the headline valuation reset. Memory is typically the fastest way for equipment demand to reaccelerate after inventory corrections, and ASML’s mix implies it should see a sharper earnings inflection than the broader semi-cap complex if DRAM node shrink continues. That creates a relative-benefit setup versus AMAT, which is more exposed to process tools that can be delayed when customers try to optimize capex, and versus TSM, which benefits from the end-market demand but not the equipment intensity uplift.

The market may still be underestimating the optionality embedded in High NA because the first-order debate is adoption timing, not economics. If the company can prove meaningful cost-per-layer advantages in the next 12-24 months, the revenue stream becomes less cyclical and more architectural, with a higher-quality multiple than peers; if adoption slips further, the stock can de-rate quickly because investors will treat the growth runway as back-end loaded. The main tail risk is not demand but sequencing: a temporary digestion phase at leading-edge customers could push orders out 1-2 quarters and create a better entry point even if the 2-3 year thesis remains intact.

Net: this looks more like an under-owned quality compounder with a cyclical kicker than a pure re-rating story. The opportunity is to own ASML into any short-term post-earnings volatility while funding it with a less differentiated equipment exposure, because the mismatch between long-duration earnings power and near-term sentiment remains wide.

Key Decisions for Investors

• Go long ASML vs short AMAT on a 3-6 month horizon: ASML should capture the higher-multiple rerating if capex breadth improves, while AMAT is more vulnerable to customer capex pauses and mix pressure.
• Buy ASML on any 1-2 day post-rally pullback or into earnings volatility; target 12-18% upside over 6-12 months with downside limited to multiple compression if High NA adoption slips again.
• Pair trade: long ASML / short TSM for 6-9 months to isolate equipment intensity upside versus foundry end-demand, which is already more fully reflected in TSM sentiment.
• For event-driven upside, consider ASML call spreads 6-12 months out rather than outright stock if implied vol is elevated; the catalyst path is gradual, so convexity should be sourced cheaply.
• If memory indicators roll over again, cut ASML aggressively: the stock’s bullish case depends on sustained DRAM node shrink, so a 1-2 quarter pause in memory capex would be the first thing to invalidate the thesis.